Abstract The pathogenesis of Parkinson’s disease (PD) remains incompletely understood, and effective early diagnostic biomarkers and disease-modifying therapies are lacking. MicroRNAs (miRNAs), a class of small non-coding RNAs, have emerged as critical regulators of gene expression involved in key pathological processes of PD, including neuronal apoptosis, mitochondrial dysfunction, oxidative stress, and α-synuclein (α-syn) aggregation. Recent evidence suggests that dysregulated miRNAs expression contributes significantly to PD progression and may serve as minimally invasive biomarkers for early diagnosis. Furthermore, miRNA-based therapeutic strategies offer promising avenues for targeting disease-related molecular pathways. This review summarizes the mechanistic roles of miRNAs in PD pathogenesis and highlights their potential clinical applications in diagnosis and therapy.
Lin et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: